علاج الخط الأول لسرطان الخلايا الكلوية الشفافة المتقدم أو المنتشر دون موانع استخدام مثبطات نقاط التفتيش المناعية

References

DOI: 10.1016/j.annonc.2024.05.537

Lenvatinib–pembrolizumab, axitinib–pembrolizumab or cabozantinib–nivolumab is recommended for first-line treatment of advanced ccRCC, irrespective of IMDC risk group.

Ipilimumab–nivolumab is recommended as first-line treatment for IMDC intermediate- and poor-risk disease and is an option for favourable-risk disease.

Axitinib–toripalimab is an option for patients with intermediate- or poor-risk disease.

In patients with a contraindication to ICIs, or where ICIs are not available, sunitinib, pazopanib or tivozanib may be used.